Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 495-502

  Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; GATIFLOXACIN; GLYCOPEPTIDE; GLYCOSIDE; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; METICILLIN; MONOBACTAM DERIVATIVE; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032871014     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598621     Document Type: Review

References (47)

1. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 1998;41:13-24.
2. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-64.
3. Feld R. Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons. Clin Infect Dis 1999;29:503-7.
4. Fruchart C, Salah A, Gray C, et al. Lactobacillus species as emerging pathogens in neutropenic patients. Eur J Clin Microbiol Infect Dis 1997;16:681-4.
5. Glauser M, Boogaerts M, Cordonnier C, Palmblad J, Martino P. Empiric therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect 1997;3(suppl 1):S77-86.
6. Johnson MP, Ramphal R. β-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infett Dis 1990; 162:981-3.
7. Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993;17(suppl 2):S332-8.
8. Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998;41:7-11.
9. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;129:508-14.
10. Rolston KVI. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999;29;515-21.
11. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4.
12. Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997. JAMA 1997;278:891-2.
13. Burwen DR, Banjeree SN, Gaynes RP, the National Nosocomial Infections Surveillance System. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170: 1622-5.
14. Cormican MG, Jones RN. Emerging resistance to antimicrobial agents in Gram-positive bacteria: enterococci, staphylococci and nonpneumococcal streptococci Drugs 1996;51(suppl 1):6-12.
15. Coronado VG, Edwards JR, Culver DH, Gaynes RP. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol 1995; 16:71-5.
16. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff K. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United Stales. Antimicrob Agents Chemother 1996;40:891-4.
17. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable monality. Clin Infect Dis 1996;23:1234-9.
18. Emori TG, Gaynes RP. An overview of nosocomial infections including the role for the microbiology laboratory. Clin Microbiol Rev 1993;6: 428-42.
19. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996;19:1445-53.
20. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;409:135-6.
21. Howe RA, Brown NM, Spencer RC. The new threats of Gram-positive pathogens: re-emergence of things of the past. J Clin Pathol 1996;49: 444-9.
22. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996;100(suppl 6A):3S-12S.
23. Knothe H, Shah P, Kromery V, Anatal M, Mitsubishi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
24. Panlilio AL, Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidcmiol 1992;13:582-6.
25. Quinn JP. Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994;13(suppl 1):39-42.
26. Spencer RC. The emergence of epidemic, multiple-antibiotic resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995;30(suppl):453-564.
27. Spencer RC, Bauemfeind A, Garcia-Rodriguez J, et al. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clinical Microbiology and Infection 1997;3(suppl 1)-S21-35.
28. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa, Antimicrob Agents Chemother 1990;34: 52-7.
29. Uttley AHC, Colins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;1:57-8.
30. Woodford N, Johnson AP, Morrison D, Speller DCE. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995;8:585-615.
31. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 4th ed. NCCLS document no. M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
32. Pfaller MA, Jones RN, Doem GV, Kugler K, the SENTRY Participants Group. Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42:1762-70.
33. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of blood stream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J Clin Microbiol 1998;36:1886-9.
34. Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Expert Opinion on Investigational Drugs 1994;3:145-71.
35. Beebe JL, Koneman EW. Recovery of uncommon bacteria from blood: association with neoplastic disease. Clin Microbiol Rev 1995;8:336-56.
36. Dholakia N, Rolston KVI, Ho DH, LeBlane B, Bodey GP. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994;38:848-52.
37. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997;24:41-51.
38. Eggiman P, Glauser MP, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993;32(suppl B):151-63.
39. American Society for Microbiology. American Society for Microbiology report of the ASM Task Force on antibiotic resistance. Antimicrob Agents Chemother 1995;(suppl 6):1-23.
40. Jones RN. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on antibiotic resistance. Diagn Microbiol Infecl Dis 1996;25:153-61.
41. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
42. Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1994;47: 471-505.
43. Tankovic J, Legrand P, DeGatines G, Chemineau V, Brun-Buisson D, Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic methods. J Clin Microbiol 1994;32:2677-81.
44. American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. Am J Respir Crit Care Med 1995;153:1711-25.
45. Francioli P, Chastre J, Langer M, Santos JI, Shah PM, Torres A. Ventilator-associated pneumonia: understanding epidemiology and pathogenesis to guide prevention and empiric therapy. Clinical Microbiology and Infection 1997;3(suppl 1):S61-76.
46. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antimicrobial agent use. Rev Infect Dis 1983;5:1033-48.
47. Wolff MJ. Use and misuse of antibiotics in Latin America. Clin Infect Dis 1993; 17(suppl 2):S346-51.